Generic Name and Formulations:
Bimatoprost 0.01%, 0.03%; oph soln; contains benzalkonium chloride.
Indications for LUMIGAN:
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
≥16yrs: 1 drop once daily in the PM.
<16yrs: not recommended.
Do not exceed recommended dose. Renal or hepatic impairment. Ocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Allow at least 5 minutes between application of other topical ophthalmic agents.
Conjunctival hyperemia, eyelash growth, ocular itching or dryness, visual disturbances, foreign body sensation, other local effects, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, blepharitis, cataract, keratitis, photophobia, infection, headache, abnormal liver function tests, asthenia, hirsutism.
Soln—2.5mL, 5mL, 7.5mL
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis